Success Metrics

Completion Rate
0%(0/1)
Active Trials
3(75%)
Terminated
1(25%)

Phase Distribution

Ph phase_2
1
25%
Ph phase_3
1
25%
Ph phase_4
2
50%

Phase Distribution

0

Early Stage

1

Mid Stage

3

Late Stage

Phase Distribution4 total trials
Phase 2Efficacy & side effects
1(25.0%)
Phase 3Large-scale testing
1(25.0%)
Phase 4Post-market surveillance
2(50.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

0.0%

0 of 1 finished

Non-Completion Rate

100.0%

1 ended early

Currently Active

3

trials recruiting

Total Trials

4

all time

Status Distribution
Active(3)
Terminated(1)

Detailed Status

Recruiting2
Active, not recruiting1
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
4
Active
3
Success Rate
0.0%
Most Advanced
Phase 4

Trials by Phase

Phase 21 (25.0%)
Phase 31 (25.0%)
Phase 42 (50.0%)

Trials by Status

active_not_recruiting125%
terminated125%
recruiting250%

Recent Activity

3 active trials
Showing 4 of 4
recruitingphase_2

Bone Loss Prevention With Zoledronic Acid or Denosumab in Critically Ill Adults

NCT04608630
active_not_recruitingphase_4

Trial of Parkinson's And Zoledronic Acid

NCT03924414
recruitingphase_4

Zoledronate Early to Hip Fracture Patients - Safe and Effective?

NCT05025293
terminatedphase_3

Denosumab Versus Zoledronic Acid in Thalassemia-Induced Osteoporosis

NCT03040765

Clinical Trials (4)

Showing 4 of 4 trials
NCT04608630Phase 2

Bone Loss Prevention With Zoledronic Acid or Denosumab in Critically Ill Adults

Recruiting
NCT03924414Phase 4

Trial of Parkinson's And Zoledronic Acid

Active Not Recruiting
NCT05025293Phase 4

Zoledronate Early to Hip Fracture Patients - Safe and Effective?

Recruiting
NCT03040765Phase 3

Denosumab Versus Zoledronic Acid in Thalassemia-Induced Osteoporosis

Terminated

All 4 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
4